Monopar Therapeutics Inc (MNPR) Annual Balance Sheets

Annual · GAAP · USD millions
Access MNPR quarterly Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Monopar Therapeutics Inc.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent61.83
Cash & Short-term Investments61.00
Other Current Assets78.63
Total Current Assets140.46
Other Assets, Noncurrent0.00
Total Assets140.72
Liabilities
Accounts Payable and Accrued Liabilities, Current LI2.74
Other Liabilities, Current0.00
Total Current Liabilities2.74
Total Long-term Debt0.00
Other liabilities, Noncurrent0.15
Total Liabilities2.89
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock227.20
Retained Earnings / Accumulated Deficit-89.51
Other Equity0.13
Common Stockholder's Equity137.83
Total Stockholder's Equity137.83
Liabilities & Stockholder's Equity140.72
4 historic quarters locked

Sign in to unlock the full Monopar Therapeutics Inc balance sheet history.

About Monopar Therapeutics Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-010025

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License